8-K: Vivos Therapeutics Appoints Gregg Johnson to Board
Director Appointment
Vivos Therapeutics, Inc. announced the appointment of Gregg C. E. Johnson as an independent director to its Board, effective February 4, 2026.
Summary
- Vivos Therapeutics, Inc. appointed Gregg C. E. Johnson as an independent director to its Board of Directors, effective February 4, 2026.
- Mr. Johnson will also serve on the Compensation Committee of the Board.
- He will receive an annual non-employee director cash fee of $48,000, plus an additional $5,000 for his committee membership, consistent with company policy.
- Mr. Johnson is eligible for stock option compensation under the Company's 2024 Equity Incentive Plan.
- He previously served as Secretary of the Company from July 2016 to July 2020 and as a director from July 2016 to March 2018.
- Mr. Johnson brings extensive experience in law, corporate compliance, senior management of high-growth companies, and capital markets advisory, including being instrumental in VirTra, Inc.'s successful NASDAQ listing.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a moderately positive development, as the appointment of an experienced independent director generally strengthens corporate governance and strategic capabilities, which is beneficial for long-term company health.
Positives
- The appointment of Gregg C. E. Johnson as an independent director enhances corporate governance.
- Mr. Johnson brings significant experience in law, corporate compliance, and senior management of high-growth entrepreneurial companies, which can benefit the company's strategic direction.
- His prior roles with the Company (Secretary, Director) suggest familiarity with Vivos Therapeutics' operations and objectives.
- Mr. Johnson's experience in guiding VirTra, Inc. to a successful NASDAQ listing indicates valuable expertise in public company development and compliance.
Management Comments
- "We believe Mr. Johnson's experience in law, business, corporate compliance and emerging companies provide the requisite qualifications, skills, perspectives, and experience that make him well qualified to serve on our Board of Directors."
Industry Context
StockSavvy.ai notes that the appointment of an experienced independent director like Gregg C. E. Johnson, with a background in corporate compliance and public company listings, is a positive step for Vivos Therapeutics. Such appointments typically aim to strengthen corporate governance, enhance strategic oversight, and potentially improve investor confidence, aligning with broader industry trends towards robust board structures, especially for emerging growth companies.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Independent Director | N/A | Gregg C. E. Johnson | 2026-02-04 | Appointment to the Board of Directors upon recommendation of the Nominating and Corporate Governance Committee. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Committee Appointment | Gregg C. E. Johnson appointed to the Compensation Committee of the Board. | 2026-02-04 | Enhances the expertise and independence of the Compensation Committee, potentially improving oversight of executive compensation practices. |
Stakeholder Impact
- Shareholders: Potentially improved corporate governance and strategic oversight due to the addition of an experienced independent director, which can contribute to long-term value creation.
Key Dates
| Date | Description |
|---|---|
| 2006-03-01 | Gregg C.E. Johnson began serving as Executive Vice President and Chief Operating Officer of SKYE International, Inc. |
| 2010-03-01 | Gregg C.E. Johnson began serving as President and Chief Executive Officer of Summit Capital Corp. and Summit Capital (USA), Inc. |
| 2010-05-31 | Gregg C.E. Johnson concluded his role as Executive Vice President and Chief Operating Officer of SKYE International, Inc. |
| 2016-07-01 | Gregg C.E. Johnson began serving as Secretary and a director of Vivos Therapeutics, Inc. |
| 2016-12-31 | Gregg C.E. Johnson concluded his role as President and Chief Executive Officer of Summit Capital Corp. and Summit Capital (USA), Inc. |
| 2018-01-01 | Gregg C.E. Johnson began serving as Chief Executive Officer of Upeva, Inc. |
| 2018-03-31 | Gregg C.E. Johnson concluded his initial term as a director of Vivos Therapeutics, Inc. |
| 2020-07-31 | Gregg C.E. Johnson concluded his role as Secretary of Vivos Therapeutics, Inc. |
| 2021-10-01 | Gregg C.E. Johnson began serving as a director and Chief Executive Officer of Serenus Global Inc. |
| 2021-11-30 | Gregg C.E. Johnson concluded his role as Chief Executive Officer of Upeva, Inc. |
| 2022-05-01 | Gregg C.E. Johnson began acting as a director of Omnia Resource Development Corporation. |
| 2024-02-29 | Gregg C.E. Johnson concluded his role as a director and Chief Executive Officer of Serenus Global Inc. |
| 2026-02-04 | Effective date of Gregg C. E. Johnson's appointment as an independent director to the Board of Directors of Vivos Therapeutics, Inc. |
| 2026-02-06 | Date of Report for the 8-K filing. |
Recommendation
holdThe appointment of an experienced independent director is a positive governance move, but it is unlikely to significantly alter the company's fundamental valuation or immediate operational trajectory. Investors should hold their position while monitoring future strategic developments and financial performance.
Keywords
Vivos Therapeutics, VVOS, Board of Directors, Director Appointment, Corporate Governance, Independent Director, Compensation Committee, SEC Filing, 8-K
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.